Skingenix, Inc., a leader in dermal regeneration technologies specializing in the research and development of polymolecular products, is located in Southern California. As an innovative and mission-driven company, Skingenix pursues a standard of excellence in the regenerative medical industry with an emphasis on developing organ in situ regenerative products for improving human health and quality of life. The Company has completed a Phase II randomized and controlled multicenter clinical study to assess the safety and efficacy of their investigational product in patients with Diabetic Foot Ulcers in the USA and currently engaged in further development of their investigational product (MW-III).
Worldwide recognition and application of organ in situ regeneration in pursuit for the realization of the best quality of health management, longer lifespan, and a secured future. The Company is dedicated to achieve this vision by combining its earned proprietary technologies and formulation of essential polymolecular products for an excellent health.
To provide cutting-edge regenerative technologies on preventing, alleviating and curing human diseases with continuing development of polymolecular products that are safe, effective and naturally regenerative in situ. Skingenix’s ultimate goals are to improve the quality of human life through the harmony of nature and science, benefit humanity, and deliver outstanding polymolecular products into the market.